Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis

Hepatology

Volumn 55, Issue 5, 2012, Pages 1495-1506

  Jin, Qinglong ^a   Moritoki, Yuki ^b   Lleo, Ana ^c,d   Tsuneyama, Koichi ^e   Invernizzi, Pietro ^c   Moritoki, Hitoshi ^f   Kikuchi, Kentaro ^g   Lian, Zhe Xiong ^h   Hirschfield, Gideon M ⁱ   Ansari, Aftab A ^j   Coppel, Ross L ^k   Gershwin, M Eric ^l   Niu, Junqi ^a  

^a JILIN UNIVERSITY   (China)

^b AKITA UNIVERSITY   (Japan)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF TOYAMA   (Japan)

^f Moritoki Laboratory of Plasticity   (Japan)

^g TEIKYO UNIVERSITY MIZONOKUCHI HOSPITAL   (Japan)

^h UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k MONASH UNIVERSITY   (Australia)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD5 ANTIGEN; MITOCHONDRION ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BILE DUCT INJURY; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; EPITHELIUM; FEMALE; HEPATITIS; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; LIVER BIOPSY; LIVER CELL; LIVER HISTOLOGY; LYMPHOCYTIC INFILTRATION; MALE; PORTAL VEIN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD20; AUTOANTIBODIES; BILE DUCTS; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; MITOCHONDRIA, LIVER; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 84859966851     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25511     Document Type: Article

References (45)

1. Gershwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ, Coppel RL. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol Rev 2000; 174: 210-225.
2. Kamihira T, Shimoda S, Harada K, Kawano A, Handa M, Baba E, et al. Distinct costimulation dependent and independent autoreactive T-cell clones in primary biliary cirrhosis. Gastroenterology 2003; 125: 1379-1387.
3. Kamihira T, Shimoda S, Nakamura M, Yokoyama T, Takii Y, Kawano A, et al. Biliary epithelial cells regulate autoreactive T cells: implications for biliary-specific diseases. HEPATOLOGY 2005; 41: 151-159.
4. Kaplan MM, Gershwin ME. Medical progress: primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-1273.
5. Shigematsu H, Shimoda S, Nakamura M, Matsushita S, Nishimura Y, Sakamoto N, et al. Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens. HEPATOLOGY 2000; 32: 901-909.
6. Shimoda S, Ishikawa F, Kamihira T, Komori A, Niiro H, Baba E, et al. Autoreactive T-cell responses in primary biliary cirrhosis are proinflammatory whereas those of controls are regulatory. Gastroenterology 2006; 131: 606-618.
7. Shimoda S, Nakamura M, Ishibashi H, Kawano A, Kamihira T, Sakamoto N, et al. Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. Gastroenterology 2003; 124: 1915-1925.
8. Shimoda S, Nakamura M, Shigematsu H, Tanimoto H, Gushima T, Gershwin ME, Ishibashi H. Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. HEPATOLOGY 2000; 31: 1212-1216.
9. Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: convenient and inconvenient truths. HEPATOLOGY 2008; 47: 737-745.
10. He X-S, Ansari AA, Ridgway WM, Coppel RL, Gershwin ME. New insights to the immunopathology and autoimmune responses in primary biliary cirrhosis. Cell Immunol 2006; 239: 1-13.
11. Nakanuma Y. Distribution of B lymphocytes in nonsuppurative cholangitis in primary biliary cirrhosis. HEPATOLOGY 1993; 18: 570-575.
12. Fregeau DR, Prindiville T, Coppel RL, Kaplan M, Dickson ER, Gershwin ME. Inhibition of alpha-ketoglutarate dehydrogenase activity by a distinct population of autoantibodies recognizing dihydrolipoamide succinyltransferase in primary biliary cirrhosis. HEPATOLOGY 1990; 11: 975-981.
13. Fregeau DR, Roche TE, Davis PA, Coppel R, Gershwin ME. Primary biliary cirrhosis. Inhibition of pyruvate dehydrogenase complex activity by autoantibodies specific for E1 alpha, a non-lipoic acid containing mitochondrial enzyme. J Immunol 1990; 144: 1671-1676.
14. Matsumura S, Van De Water J, Leung P, Odin JA, Yamamoto K, Gores GJ, et al. Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis. HEPATOLOGY 2004; 39: 1415-1422.
15. Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, Mackay IR, et al. Apotopes and the biliary specificity of primary biliary cirrhosis. HEPATOLOGY 2009; 49: 871-879.
16. Lleo A, Bowlus CL, Yang GX, Invernizzi P, Podda M, Van de Water J, et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. HEPATOLOGY 2010; 52: 987-998.
17. Kita H, Lian ZX, Van de Water J, He XS, Matsumura S, Kaplan M, et al. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med 2002; 195: 113-123.
18. Neuberger J. Liver transplantation for primary biliary cirrhosis. Autoimmun Rev 2003; 2: 1-7.
19. Chuang YH, Lian ZX, Yang GX, Shu SA, Moritoki Y, Ridgway WM, et al. Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. HEPATOLOGY 2008; 47: 571-580.
20. Oertelt S, Lian Z-X, Cheng C-M, Chuang Y-H, Padgett KA, He X-S, et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006; 177: 1655-1660.
21. Moritoki Y, Lian ZX, Lindor K, Tuscano J, Tsuneyama K, Zhang W, et al. B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. HEPATOLOGY 2009; 50: 1893-1903.
22. Moteki S, Leung PS, Coppel RL, Dickson ER, Kaplan MM, Munoz S, Gershwin ME. Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. HEPATOLOGY 1996; 24: 97-103.
23. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987; 138: 3525-3531.
24. Dahnrich C, Pares A, Caballeria L, Rosemann A, Schlumberger W, Probst C, et al. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem 2009; 55: 978-985.
25. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. HEPATOLOGY 2009; 50: 291-308.
26. Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y. Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol 2004; 17: 1141-1149.
27. Dalloul A. CD5: a safeguard against autoimmunity and a shield for cancer cells. Autoimmun Rev 2009; 8: 349-353.
28. Hardy RR. B-1 B cells: development, selection, natural autoantibody, and leukemia. Curr Opin Immunol 2006; 18: 547-555.
29. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008; 224: 201-214.
30. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006; 176: 705-710.
31. Shimomura Y, Mizoguchi E, Sugimoto K, Kibe R, Benno Y, Mizoguchi A, Bhan AK. Regulatory role of B-1 B cells in chronic colitis. Int Immunol 2008; 20: 729-737.
32. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118: 3420-3430.
33. Renaudineau Y, Hillion S, Saraux A, Mageed RA, Youinou P. An alternative exon 1 of the CD5 gene regulates CD5 expression in human B lymphocytes. Blood 2005; 106: 2781-2789.
34. Garaud S, Le Dantec C, de Mendoza AR, Mageed RA, Youinou P, Renaudineau Y. IL-10 production by B cells expressing CD5 with the alternative exon 1B. Ann N Y Acad Sci 2009; 1173: 280-285.
35. Gregorio GV, Pensati P, Iorio R, Vegnente A, Mieli-Vergani G, Vergani D. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998; 112: 471-476.
36. Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999; 45: 435-441.
37. Sansonno D, Lauletta G, Montrone M, Grandaliano G, Schena FP, Dammacco F. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. Clin Exp Immunol 2005; 140: 498-506.
38. Panasiuk A, Prokopowicz D, Zak J, Wysocka J. Peripheral blood T, B, and NK cells in relation to histological hepatitis activity and fibrosis stage in chronic hepatitis C. Hepatogastroenterology 2003; 50: 178-182.
39. Curry MP, Golden-Mason L, Doherty DG, Deignan T, Norris S, Duffy M, et al. Expansion of innate CD5pos B cells expressing high levels of CD81 in hepatitis C virus infected liver. J Hepatol 2003; 38: 642-650.
40. Curry MP, Golden-Mason L, Nolan N, Parfrey NA, Hegarty JE, O'Farrelly C. Expansion of peripheral blood CD5+ B cells is associated with mild disease in chronic hepatitis C virus infection. J Hepatol 2000; 32: 121-125.
41. Mizuochi T, Ito M, Takai K, Yamaguchi K. Differential susceptibility of peripheral blood CD5+ and CD5- B cells to apoptosis in chronic hepatitis C patients. Biochem Biophys Res Commun 2009; 389: 512-515.
42. Toubi E, Kessel A, Peri R, Shmuel Z, Bamberger E, Sabo E, Zuckerman E. Enhanced apoptosis of peripheral CD5-negative B lymphocytes from chronically hepatitis C virus-infected patients: reversal after antiviral treatment. J Virol 2004; 78: 11379-11384.
43. Walewska-Zielecka B, Madalinski K, Jablonska J, Godzik P, Cielecka-Kuszyk J, Litwinska B. Composition of inflammatory infiltrate and its correlation with HBV/HCV antigen expression. World J Gastroenterol 2008; 14: 4040-4046.
44. Yamada H, Shimizu H, Taniguchi O, Okumura K. Leu-1(CD5) B cell subpopulation in patients with various liver diseases-special reference to hepatitis B virus carrier and to changes caused by prednisolone therapy. Int Arch Allergy Appl Immunol 1988; 87: 409-416.
45. Kita H, Matsumura S, He XS, Ansari AA, Lian ZX, Van de Water J, et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest 2002; 109: 1231-1240.